Peripheral Administration of GSK-3β Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 54, Issue 4, 2016, Pages 1339-1348

  Farr, Susan A ^a,b   Sandoval, Karin E ^c   Niehoff, Michael L ^b   Witt, Ken A ^c   Kumar, Vijaya B ^a,b   Morley, John E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Antisense; GSK 3 ; learning; memory; SAMP8; tau

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLYCOGEN SYNTHASE KINASE 3BETA; SERINE; TYROSINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DECLARATIVE MEMORY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; LEARNING; MALE; MEMORY; MOUSE; MOUSE MODEL; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; T-MAZE TEST; TG2576 MOUSE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL AGING; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; MAZE TEST; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CELLULAR SENESCENCE; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3 BETA; MALE; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84992124390     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160416     Document Type: Article

References (45)

1. Kaidanovich-Beilin O, Woodgett JR (2011) GSK-3: Functional insights from cell biology and animal models. Front Mol Neurosci 4, 40
2. Hooper C, Killick R, Lovestone S (2008) TheGSK3hypothesis of Alzheimers disease. J Neurochem 104, 1433-1439
3. Martinez A, Gil C, Perez DI (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimers disease treatment. Int J Alzheimers Dis 2011, 1-7
4. Xi YL, Li HX, Chen C, Liu YQ, Lv HM, Dong SQ, Luo EF, Gu MB, Liu H (2016) Baicalin attenuates high fat dietinduced insulin resistance and ectopic fat storage in skeletal muscle, through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway. Chin J Nat Med 14, 48-55
5. Li B, Thrasher JB, Terranova P (2015) Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. Urol Oncol 33, 456-463
6. Lazzara CA, Kim YH (2015) Potential application of lithium in Parkinsons and other neurodegenerative diseases. Front Neurosci 9, 403
7. Forlenza OV, De-Paula VJ, Diniz BS (2014) Neuroprotective effects of lithium: Implications for the treatment of Alzheimers disease and related neurodegenerative disorders. ACS Chem Neurosci 5, 443-450
8. Medina M, Avila J (2013) Understanding the relationship between GSK-3 and Alzheimers disease: A focus on how GSK-3 can modulate synaptic plasticity processes. Expert Rev Neurother 13, 495-503
9. Llorens-Martin M, Jurado J, Hernandez F, Avila J (2014) GSK-3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7, 46
10. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19, 1221-1229
11. Hanger DP, Noble W (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011, 352805
12. Yagi H, Katoh S, Akiguchi I, Takeda T (1988) Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Neurosci Biobehav Rev 474, 86-93
13. Flood JF, Morley JE (1998) Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 22, 1-20
14. Morley JE, Kumar VB, Bernardo AI, Farr SA, Uezu K, Tumosa N, Flood JF (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 21, 1761-1767
15. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimers disease: Unveiling "the switch" with the senescenceaccelerated mouse model (SAMP8). J Alzheimers Dis 15, 615-624
16. Butterfield DA, Stadtman ER (1997) Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2, 161-191
17. Poon HF, Castegna A, Farr SA, Thongbookerd V, Lynn BC, Banks WA, Morley JE, Klein JB, Butterfield DA (2004) Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescenceaccelerated-prone 8 mouse brain. Neuroscience 126, 915-926
18. Erickson MA, Niehoff ML, Farr SA, Morley JE, Dillman LA, Lynch KM, Banks WA (2012) Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses ABPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 28, 951-960
19. Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, Murphy MP, Morley JE, Kumar V, Butterfield DA (2014) Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67, 387-395
20. Tajes M, Yeste-Velasco M, Zhu X, Chou SP, Smith MA, Pallas M, Camins A, Casadesus G (2009) Activation of Akt by lithium: Pro-survival pathways in aging. Mech Ageing Dev 130, 253-261
21. Hsaio K, Chapman P, Nilsen S, Erkman C, Harigaya Y, Yang F, Cole G (1996) Correlative memory deficits, AB elevation, and amyloid plaques in transgenic mice. Science 274, 99-102
22. Dobarro M, Gerenu G, Ramierz MJ (2013) Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimers transgenic mice. Int J Neuropsychopharmacol 16, 2245-2257
23. Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, Kayed R (2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimers disease mouse model. J Neurosci 35, 4857-4868
24. Hammond RS, Tull LE, Stackman RW (2004) On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82, 26-34
25. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, Woodgett JR, Miller CCJ (1994) Alzheimers disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4, 1077-1086
26. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92, 232-241
27. Hong M, Chen DC, Klein PS, Lee VM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326-25332
28. Engel T, Goni-Oliver P, Lucas JJ, Avila F, Hernandez F (2006) Chronic lithium administration of FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99, 1445-1455
29. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39
30. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56, 70-78
31. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimers disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Applied Neurobiol 33, 43-55
32. Fu ZQ, Yang Y, Song J, Jiang Q, Lin ZC, Wang Q, Zhu LQ, Wang JZ, Tian Q (2010) LiCl attenuates thapsigargininduced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro. J Alzheimers Dis 21, 1107-1117
33. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F (2010) Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One 5, e14382
34. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry 198, 351-356
35. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-1019
36. Blalock EM, Geddes JW, Chen KC, Porter NM,Markesbery WR, Landfield PW (2004) Incipient Alzheimers disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101, 2173-2178
37. Kanno T, Tsuchiya A, Nishizaki T (2014) Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav Brain Res 274, 302-306
38. Sanna PP, Cammalleri M, Berton F, Simpson C, Lutjens R, Bloom FE, Francesconi W (2002) Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J Neurosci 22, 3359-3365
39. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87, 1333-1344
40. Armbrecht HJ, Siddiqui AM, Green M, Farr SA, Kumar VB, Banks WA, Patrick P, Shah GN, Morley JE (2014) SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways. Neurobiol Aging 35, 159-168
41. Jope RS, Yukaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 32, 577-595
42. Tamm I (2008) AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for potential tretment of cancer. Curr Opin Investig Drugs 9, 638-646
43. Evers MM, Toonen LJ, Roon-Mom WM (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87, 90-103
44. Lippi G, Harenberg J,Mattiuzzi C, Favaloro EJ (2015) Next generation antithrombotic therapy: Focus on antisense therapy against coagulation factor XI. Semin Thromb Hemost 41, 255-262
45. Davalos A, Chroni A (2015) Antisense oligonucleotides, microRNAs, and antibodies. Handb Exp Pharmacol 224, 649-689